Sentinel node biopsy for melanoma: New Zealand indication guidelines in practice✰

Brian, Tess; McEwan, Winston; Jameson, Michael B.

doi:10.1016/j.bjps.2018.10.001

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9][10] Compliance with the NZ melanoma SLNB guidelines were audited in 2016 at a tertiary NZ hospital which concluded SLNB practices were in keeping with practice guidelines, accounting for the influences of patient age, wishes, comorbidities and surgeon preference. 43 SLNB for melanoma has now been in practice for over 25 years. During this time, indications for SLNB have changed along with the management of positive SNs.…”

Section: Discussionmentioning

confidence: 99%

“…Our current recommendations are in agreement with the standards set by international melanoma guidelines (Australian and New Zealand Clinical Practice Guidelines for the Management of Melanoma, NZ Standards of Service Provision for Melanoma Patients, Cancer Council Australia Melanoma Guidelines, NICE Melanoma Assessment and Management Guidelines, National Comprehensive Cancer Network Practice Guidelines for Cutaneous Melanoma and Cancer Care Ontario and Canadian Medical Association Melanoma Guidelines) 5–10 . Compliance with the NZ melanoma SLNB guidelines were audited in 2016 at a tertiary NZ hospital which concluded SLNB practices were in keeping with practice guidelines, accounting for the influences of patient age, wishes, comorbidities and surgeon preference 43 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma

Wen

Martin

2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background: Melanoma is a leading cause of morbidity and mortality in Australia and New Zealand. New Zealand has the highest melanoma incidence in the world alongside Australia at 54 per 100 000 persons. The aim of this study is to conduct a retrospective quality audit of sentinel lymph nodal biopsy (SLNB) practices from 2007 to 2019 of a high-volume melanoma surgeon. Primary outcome was false negative rate (FNR). Secondary outcomes were sentinel node (SN) identification and removal rate, and complication rates. Methods: A database was maintained, containing n = 553 consecutive SLNB's for cutaneous melanoma from 31 August 2007 to 31 August 2019. Patient characteristics and details of the primary lesion, sentinel lymph node biopsy, recurrence and complications were recorded. Results: SN's were successfully identified in 444 (99.6%) out of 446 patients with an FNR of 9.1%. Positive SN's were identified in 70 (12.7%) SLNB's. Complications occurred in 76 out of 553 (13.7%) SLNB's. A review of internationally published literature reveals an SN identification rate of 94.4-99.5% with an FNR of 4.0-37.5%. SLNB is the best staging tool for melanoma and gives potential access to adjuvant systemic treatment if >1 mm deposits are found. It is a day-stay procedure with a low-complication rate. Conclusion: SLNB is a safe and reliable procedure utilized for cutaneous melanoma. We propose our data should be used alongside international SN series to establish Quality Performance Indicators to improve melanoma management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%